Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 in adult human immunodeficiency virus (HIV) infected female subjects.

Trial Profile

Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 in adult human immunodeficiency virus (HIV) infected female subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04B
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 Sep 2013 Results published in the Vaccine.
    • 18 Jul 2012 Primary outcome amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top